[go: up one dir, main page]

CY1112460T1 - Φαρμακευτικα μεσα που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη και διεργασιες για την παρασκευη αυτων - Google Patents

Φαρμακευτικα μεσα που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη και διεργασιες για την παρασκευη αυτων

Info

Publication number
CY1112460T1
CY1112460T1 CY20121100233T CY121100233T CY1112460T1 CY 1112460 T1 CY1112460 T1 CY 1112460T1 CY 20121100233 T CY20121100233 T CY 20121100233T CY 121100233 T CY121100233 T CY 121100233T CY 1112460 T1 CY1112460 T1 CY 1112460T1
Authority
CY
Cyprus
Prior art keywords
trendric
bardenenaphil
hydrochlorine
procedures
preparation
Prior art date
Application number
CY20121100233T
Other languages
English (en)
Inventor
Peter Serno
Alfons Grunenberg
Andreas Ohm
Rainer Bellinghausen
Eimer Vollers
Jan-Olav Henck
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29796385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112460(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of CY1112460T1 publication Critical patent/CY1112460T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μία μέθοδο για την παρασκευή φαρμακευτικών μέσων που περιέχουν υδροχλωρική βαρντεναφίλη, κατ' ουσίαν ως τριϋδρικό άλας σε στερεή μορφή, και σε φαρμακευτικά μέσα τα οποία μπορούν να ληφθούν σύμφωνα με τη μέθοδο αυτή.
CY20121100233T 2002-07-16 2012-03-08 Φαρμακευτικα μεσα που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη και διεργασιες για την παρασκευη αυτων CY1112460T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10232113A DE10232113A1 (de) 2002-07-16 2002-07-16 Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
EP03763695A EP1523303B1 (de) 2002-07-16 2003-07-03 Vardenafil hydrochlorid trihydrat enthaltende arzneimittel und deren herstellungsverfahren

Publications (1)

Publication Number Publication Date
CY1112460T1 true CY1112460T1 (el) 2015-12-09

Family

ID=29796385

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100233T CY1112460T1 (el) 2002-07-16 2012-03-08 Φαρμακευτικα μεσα που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη και διεργασιες για την παρασκευη αυτων
CY20161101342T CY1118394T1 (el) 2002-07-16 2016-12-23 Δισκια που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20161101342T CY1118394T1 (el) 2002-07-16 2016-12-23 Δισκια που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη

Country Status (31)

Country Link
US (2) US8273876B2 (el)
EP (2) EP1523303B1 (el)
JP (2) JP5173113B2 (el)
KR (2) KR20100137572A (el)
CN (2) CN1681481B (el)
AT (1) ATE538777T1 (el)
AU (1) AU2003249942B2 (el)
BR (1) BRPI0305559B8 (el)
CA (2) CA2805600C (el)
CU (1) CU23473B7 (el)
CY (2) CY1112460T1 (el)
DE (1) DE10232113A1 (el)
DK (2) DK1523303T3 (el)
EC (1) ECSP055541A (el)
ES (2) ES2609593T3 (el)
HR (3) HRP20120418B1 (el)
HU (1) HUE032362T2 (el)
IL (2) IL166162A (el)
LT (1) LT2272505T (el)
MA (1) MA27320A1 (el)
MX (1) MXPA05000554A (el)
NO (2) NO335434B1 (el)
NZ (1) NZ537698A (el)
PH (1) PH12012501171A1 (el)
PL (1) PL223341B1 (el)
PT (2) PT1523303E (el)
RU (1) RU2349306C2 (el)
SI (2) SI2272505T1 (el)
UA (1) UA85542C2 (el)
WO (1) WO2004006894A1 (el)
ZA (1) ZA200500268B (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
JP4540295B2 (ja) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 ｐｄｅ 억제제
DE102007034741A1 (de) * 2007-07-25 2009-01-29 Siemens Ag Elektrische Maschine mit Öffnungen im Lagerschildunterteil
PL390079A1 (pl) 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
CZ2011767A3 (cs) 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
CN103372014B (zh) * 2012-04-26 2015-10-21 齐鲁制药有限公司 一种能快速溶出、稳定的盐酸伐地那非口服固体制剂及其制备方法
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
EP3043793B1 (en) * 2013-11-19 2021-01-06 Siga Technologies Inc. Rehydration of micronized tecovirimat monohydrate
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
JP2021506986A (ja) 2017-12-20 2021-02-22 クラリア・ファルマ・ホールディング・アクチボラグ バルデナフィルを含むフィルム配合物、その調製法、およびその使用
JP7336241B2 (ja) * 2019-04-02 2023-08-31 富士化学工業株式会社 バルデナフィル含有錠剤の製造方法
CN110507626B (zh) * 2019-09-19 2020-08-18 山东创新药物研发有限公司 一种稳定的盐酸伐地那非三水合物药物组合物的制备方法
WO2021175250A1 (en) * 2020-03-03 2021-09-10 Aptorum Therapeutics Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
CN114948968A (zh) * 2021-02-22 2022-08-30 南京佰麦生物技术有限公司 一种稳定的三水合盐酸伐地那非药物组合物

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
GB790762A (en) * 1953-08-28 1958-02-19 Arthur Poole A hydrate of lignocaine hydrochloride and process for making it
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (el) 1963-01-16
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (da) 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DE3166627D1 (en) 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
EP0347146B1 (en) 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
EP0524180B1 (en) 1990-04-11 1995-04-26 The Upjohn Company Taste masking of ibuprofen by fluid bed coating
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4120322A1 (de) * 1991-06-20 1992-12-24 Bayer Ag Aminomethyl-substituierte 2,3-dihydropyrano(2,3-b)pyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
IL105553A (en) 1992-05-06 1998-01-04 Janssen Pharmaceutica Inc Solid dosage form comprising a porous network of matrix forming material which disperses rapidly in water
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
CA2148260A1 (en) 1993-09-10 1995-03-16 Yasutaka Takase Quinazoline cpompounds
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CN1080721C (zh) * 1995-07-03 2002-03-13 旭化成株式会社 1－(5－异喹啉磺酰基)高哌嗪盐酸盐水合物
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
TW438608B (en) * 1995-08-02 2001-06-07 Hisamitsu Pharmaceutical Co A tablet containing anion exchange resin
JP3182685B2 (ja) * 1995-09-01 2001-07-03 北陸製薬株式会社 水和物結晶及びその製造方法
DE19540642A1 (de) 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
GB9612514D0 (en) 1996-06-14 1996-08-14 Pfizer Ltd Novel process
CN1230883A (zh) * 1996-09-24 1999-10-06 伊莱利利公司 包衣颗粒制剂
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE19812462A1 (de) 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6221402B1 (en) 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
EP0945134A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
GT199900061A (es) 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
CA2346350C (en) 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
FR2785538B1 (fr) 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000057857A1 (en) 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
JP2001106674A (ja) * 1999-05-13 2001-04-17 Nikken Chem Co Ltd 塩酸イピダクリン水和物の製造方法
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6075028A (en) 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
GB9923968D0 (en) 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
JP2003519150A (ja) 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト 新規なイミダゾ［１，３，５］トリアジノン類及びその使用
US6362478B1 (en) * 2000-02-14 2002-03-26 General Electric Company Radiation detector signal pulse clipping
WO2001078781A2 (en) 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
AU2001273545A1 (en) 2000-07-19 2002-01-30 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
EP1307201B1 (de) 2000-08-01 2004-11-24 Bayer HealthCare AG Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
WO2002036126A1 (en) 2000-10-30 2002-05-10 Lupin Limited Rapidly disintegrating sustained release cefuroxime axetil composition
US20020091129A1 (en) 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
IN192750B (el) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
DE10063108A1 (de) 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
WO2002062315A1 (en) 2001-02-08 2002-08-15 Pharmacia Corporation Rapid-onset medicament for the treatment of sexual dysfunction
JP4179784B2 (ja) 2001-02-15 2008-11-12 田辺三菱製薬株式会社 口腔内速崩壊性錠
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
JP4540295B2 (ja) 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ２−フェニル置換イミダゾトリアジノンの新しい用途
AU2002255321B2 (en) 2001-05-10 2007-05-17 Astellas Pharma Inc. Tablets quickly disintegrating in the oral cavity and process for producing the same
MXPA03000985A (es) 2001-07-27 2004-04-02 Yamanouchi Pharma Co Ltd Composicion que comprende particulas finas de liberacion sostenida para tabletas de desintegracion rapida en la cavidad bucal y metodo de fabricacion de la misma.
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
GB0204771D0 (en) 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
US7939102B2 (en) 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
GB0219516D0 (en) 2002-08-21 2002-10-02 Phoqus Ltd Fast dissolving and taste masked oral dosage form comprising sildenafil
US8263126B2 (en) 2003-06-06 2012-09-11 Ethypharm Orally-dispersible multilayer tablet
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
US6980922B2 (en) * 2003-10-09 2005-12-27 Computational Biodynamics, Llc Computer simulation model for determining damage to the human central nervous system
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
MXPA06012564A (es) 2004-04-27 2007-01-31 Medicinova Inc Derivados de acido fenoxialquilcarboxilico en el tratamiento de enfermedades inflamatorias.
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
US20060105039A1 (en) 2004-10-21 2006-05-18 Jin-Wang Lai Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
EP1817009A2 (en) 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20070031349A1 (en) 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
WO2007029376A1 (ja) 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤

Also Published As

Publication number Publication date
CA2492747A1 (en) 2004-01-22
KR101552418B1 (ko) 2015-09-10
DE10232113A1 (de) 2004-01-29
BRPI0305559B1 (pt) 2019-09-03
HRP20131002A2 (hr) 2014-03-28
ECSP055541A (es) 2005-03-10
KR20130137723A (ko) 2013-12-17
JP5173113B2 (ja) 2013-03-27
IL232538A0 (en) 2014-06-30
ATE538777T1 (de) 2012-01-15
RU2005103820A (ru) 2005-08-10
MA27320A1 (fr) 2005-05-02
PT2272505T (pt) 2017-01-10
ES2378358T3 (es) 2012-04-11
US8841446B2 (en) 2014-09-23
EP2272505B1 (de) 2016-10-12
CY1118394T1 (el) 2017-06-28
HRP20050143B1 (hr) 2014-01-31
SI2272505T1 (sl) 2017-01-31
JP2005533836A (ja) 2005-11-10
UA85542C2 (ru) 2009-02-10
EP1523303A1 (de) 2005-04-20
US20130078306A1 (en) 2013-03-28
RU2349306C2 (ru) 2009-03-20
CA2492747C (en) 2013-02-12
AU2003249942A1 (en) 2004-02-02
JP2013063982A (ja) 2013-04-11
HUE032362T2 (en) 2017-09-28
HRP20120418A2 (hr) 2012-06-30
PL374694A1 (en) 2005-10-31
NO337043B1 (no) 2016-01-11
CU23473B7 (es) 2009-12-17
PL223341B1 (pl) 2016-10-31
CN1681481B (zh) 2010-12-15
CA2805600A1 (en) 2004-01-22
WO2004006894A1 (de) 2004-01-22
NO20141272L (no) 2005-02-02
PH12012501171A1 (en) 2016-01-11
CN1681481A (zh) 2005-10-12
EP2272505A1 (de) 2011-01-12
IL166162A0 (en) 2006-01-15
ZA200500268B (en) 2006-03-29
NZ537698A (en) 2006-10-27
US8273876B2 (en) 2012-09-25
HRP20120418B1 (hr) 2018-01-26
NO20050578L (no) 2005-02-02
LT2272505T (lt) 2017-01-25
DK1523303T3 (da) 2012-04-10
AU2003249942B2 (en) 2009-10-29
HRP20050143A2 (en) 2005-06-30
PT1523303E (pt) 2012-03-08
MXPA05000554A (es) 2005-04-28
KR20100137572A (ko) 2010-12-30
CA2805600C (en) 2018-12-18
CN102210689A (zh) 2011-10-12
US20060111354A1 (en) 2006-05-25
CN102210689B (zh) 2014-07-30
IL166162A (en) 2014-05-28
NO335434B1 (no) 2014-12-15
DK2272505T3 (en) 2017-01-23
ES2609593T3 (es) 2017-04-21
EP1523303B1 (de) 2011-12-28
SI1523303T1 (sl) 2012-06-29
BR0305559A (pt) 2004-09-28
BRPI0305559B8 (pt) 2021-05-25
HK1084019A1 (en) 2006-07-21

Similar Documents

Publication Publication Date Title
CY1112460T1 (el) Φαρμακευτικα μεσα που περιεχουν τριϋδρικη υδροχλωρικη βαρντεναφιλη και διεργασιες για την παρασκευη αυτων
ATE323478T1 (de) Pharmazeutische pellets enthaltend tamsulosin sowie deren herstellungsverfahren
TNSN08279A1 (en) Bayer healthcare ag
BR0015765A (pt) Processo para a produção de uma massa de batata laminável a partir de um estoque de batatas cruas, massa de batata laminável e produto de batata aperfeiçoado
HU0105316D0 (en) Medical and food products for treating diabetes mellitus and process for producing thereof
DE59101776D1 (de) Verfahren zur Herstellung klein dimensionierter Formkörper mit hohem Etofibrat-Gehalt und kontrollierter Wirkstoff-Freisetzung, deren Verwendung und daraus bestehende oral verabreichbare Applikationsformen.
DE3882135D1 (de) Verwendung von melatonin oder seine derivate zur herstellung von arzneimitteln, die gegen alterskrankheiten wirksam sind.
ATE381929T1 (de) Verwendung von resveratrol zur herstellung eines arzneimittels zur behandlung von grippe
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE309981T1 (de) Gallensäure-substituierte phenyl- alkenoylguanidine, verfahren zu ihrer herstellung,ihre verwendung als medikamente oder diagnostika sowie sie enthaltende medikamente
MXPA03004537A (es) Derivados sustituidos con ciclohexano y uso de los mismos en medicamentos para tratar enfermedades cardiovasculares.
SE9903771D0 (sv) Medel och förfarande för bekämpning av sjukdomstillstånd i matsmältningsapparaten, förfarande för framställning av och användning av ett preparat som ettt sådant medel, samt djufoder och förfarande för framställning av ett djurfoder
ATE497003T1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht
MA27476A1 (fr) Procede et appareil de production d'un produit cimentaire multicouche
ATE445394T1 (de) Verwendung von citrullin zur herstellung eines arzneimittels zur behandlung von ans altern oder an eine bestrahlung gebundener intestinaler insuffizienz
FR2874502B1 (fr) Nouvel extrait vegetal, son procede d'obtention et ses applications pharmaceutiques, nutraceutiques ou cosmetiques
ATE410173T1 (de) Produkt pflanzlichen ursprungs, das proanthocyane enthält, sowie verfahren zu seiner herstellung
ATE517881T1 (de) 1-phenyl-2-heteroaryl-substituierte benzimidazolderivate, deren verwendung zur herstellung von arzneimitteln zur behandlung von immunologischen erkrankungen
MA27171A1 (fr) Dihydro-thia-phenanthrene-darbonyl-guanidines, procede de production desdites substances et leur utilisation en tant que medicament ou produit de diagnostic, et medicament contenant lesdites substances
SE9900846D0 (sv) Medel för bekämpning av sjukdomstillstånd i matsmältningsapparaten, förfarande för framställning därav samt användning
CO5690559A2 (es) Bayer healthcare ag. medicamentos que contienen clorhidrato de vardenafilo trihidrato
UA39141C2 (uk) Засіб "кратал" для лікування захворювань серцево- судинної системи
CY1116030T1 (el) Μεθοδος για την παραγωγη φαρμακευτικων προϊοντων
TW200638941A (en) Processing method of nano preparation of Chinese herbal antibiotic drug
DE502004010174D1 (de) Hautpflegeprodukt